# Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib as First-Line Therapy for Advanced HER2-Positive/HER2-Low Biliary Tract Cancer

> **NCT07670273** · PHASE2 · RECRUITING · sponsor: **Peking Union Medical College Hospital** · enrollment: 70 (estimated)

## Conditions studied

- Biliary Tract Neoplasms Immunotherapy

## Interventions

- **DRUG:** Trastuzumab Rezetecan
- **DRUG:** Adebrelimab
- **DRUG:** Lenvatinib

## Key facts

- **NCT ID:** NCT07670273
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-29
- **Primary completion:** 2027-04-29
- **Final completion:** 2028-04-29
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2026-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07670273

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07670273, "Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib as First-Line Therapy for Advanced HER2-Positive/HER2-Low Biliary Tract Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07670273. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*